Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease

Preclinical Study Examines Relationship Between Aging Breast Tissue and Invasive Breast Cancer

Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment in Metastatic Colorectal Cancer 60-Day Mortality

First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer

Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis